|
Russell-Silver syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
As a Silver-Russell syndrome (SRS) locus has been proposed to be located to a region near MEST and to be involved in imprinting, CPA4 would have been a candidate gene for SRS.
|
12552318 |
2003 |
|
Russell-Silver syndrome
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
As CPA4 has a potential role in cell proliferation and differentiation, two preferentially expressed copies in mUPD patients with SRS syndrome would result in excess expression and could alter the growth profiles of these subjects and give rise to intrauterine growth restriction.
|
12676894 |
2003 |
|
Prostate Cancer, Hereditary, 7
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings support that CPA4 is imprinted and may become a strong candidate gene for prostate cancer-aggressiveness.
|
12552318 |
2003 |
|
Fetal Growth Retardation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
As CPA4 has a potential role in cell proliferation and differentiation, two preferentially expressed copies in mUPD patients with SRS syndrome would result in excess expression and could alter the growth profiles of these subjects and give rise to intrauterine growth restriction.
|
12676894 |
2003 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
In contrast, in 9L tumors expressing P450 2B11, a low K(m) CPA 4-hydroxylase, intratumoral 4-OH-CPA levels were higher than in blood, liver and P450-deficient tumors.
|
17853921 |
2007 |
|
Prostate Cancer, Hereditary, 7
|
0.020 |
Biomarker
|
disease |
BEFREE |
Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness.
|
19245716 |
2009 |
|
Malignant neoplasm of prostate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The nonsynonymous coding SNP (rs2171492, rs2171492" genes_norm="51200">Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years).
|
19245716 |
2009 |
|
Prostate carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The nonsynonymous coding SNP (rs2171492, rs2171492" genes_norm="51200">Cys303Gly) in CPA4 was associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years).
|
19245716 |
2009 |
|
Asthma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Genes related to epithelial repair and mast cell infiltration including beta-tryptase and carboxypeptidase A3 were upregulated by exercise challenge in the asthma group with EIB.
|
20052409 |
2010 |
|
Mastocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein we have identified local mastocytosis and mast cell degranulation in the esophagi of patients with EE; identified an esophageal mast cell-associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, with carboxypeptidase A3 mRNA levels serving as the best mast cell surrogate marker; and provided evidence for the involvement of KIT ligand in the pathogenesis of EE.
|
20538331 |
2010 |
|
Eosinophilic esophagitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein we have identified local mastocytosis and mast cell degranulation in the esophagi of patients with EE; identified an esophageal mast cell-associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, with carboxypeptidase A3 mRNA levels serving as the best mast cell surrogate marker; and provided evidence for the involvement of KIT ligand in the pathogenesis of EE.
|
20538331 |
2010 |
|
Nasal Polyps
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The mast cells detected in the epithelium in NPs were characterized by the expression of tryptase and carboxypeptidase A3 but not chymase.
|
22534535 |
2012 |
|
Asthma
|
0.020 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Pulmonary Eosinophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Asthmatic pulmonary eosinophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Neutrophilic asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Paucigranulocytic asthma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Cystic Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, p.Tyr263Cys tend to be more frequently observed in CF patients with CPA than in patients without CPA (4/68 vs 0/35), and DCTN4 missense variants tend to be more frequent in male CF patients with CPA bearing two class II mutations than in male CF patients without CPA bearing two class II mutations (P = 0.06).
|
25763772 |
2016 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CPA4 was closely associated with the putative cancer stem cell marker ALDH1A1 and might be used as an independent prognostic factor in ESCC.
|
28475748 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
This study is aimed at investigating the expression of carboxypeptidaseA4 (CPA4) and aldehyde dehydrogenase 1A1 (ALDH1A1) in esophageal squamous cell carcinoma (ESCC) tumor tissues and analyzed their association and clinical significance.
|
28475748 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Overexpression of CPA4 was closely associated with the putative cancer stem cell marker ALDH1A1 and might be used as an independent prognostic factor in ESCC.
|
28475748 |
2017 |
|
Adult Liver Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |
|
Malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |
|
Hepatitis
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aimed to evaluate the expression of carboxypeptidase 4 (CPA4) in hepatitis, liver cirrhosis and liver cancer tissues, and revealed its clinical significance in liver cancer progression.
|
28123604 |
2017 |